Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Sponsor: The University of Texas Health Science Center at San Antonio
Summary
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Official title: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-01-13
Completion Date
2027-03-31
Last Updated
2026-04-06
Healthy Volunteers
No
Interventions
Empagliflozin 25 MG
Empagliflozin 25MG will be administered orally once per day for 3 months
Placebo
The placebo will be administered orally once per day for 3 months
Locations (1)
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States